Related Experiment Videos
Ongoing osteolysis in patients with lymphangioma
1Division of Surgery, Children's Research Hospital, Kyoto Prefectural University of Medicine, Japan.
Journal of Pediatric Surgery
|February 24, 1998
Summary
Severe osteolysis, a rare lymphangioma complication, can be fatal. OK-432 therapy showed promise, halting osteolysis in some patients, but outcomes varied significantly.
Area of Science:
- Oncology
- Pediatric Oncology
- Skeletal Biology
Background:
- Lymphangiomas, benign tumors of lymphatic vessels, can rarely cause severe osteolysis.
- Osteolysis, the breakdown of bone tissue, is a serious complication that can lead to significant morbidity and mortality.
- This study investigates the clinical course and treatment response in patients with lymphangioma-associated osteolysis.
Observation:
- Four pediatric patients presented with massive osteolysis and severe complications secondary to lymphangioma.
- Complications included life-threatening pleural effusion and extensive bone destruction.
- The extent of osteolysis ranged from cervical to appendicular bones.
Findings:
- Two patients treated with OK-432 (a streptococcal preparation) demonstrated arrest of osteolysis.
- One patient experienced complete recovery from pleural effusion following OK-432 therapy.
- Two patients did not respond to OK-432; one succumbed to progressive osteolysis, while the other developed extensive leg osteolysis.
Implications:
- OK-432 therapy may be a viable treatment option for lymphangioma-associated osteolysis, offering potential for disease arrest.
- Treatment response can be variable, highlighting the need for individualized management strategies.
- Severe, progressive osteolysis can result in significant functional impairment and potentially fatal outcomes, underscoring the importance of early diagnosis and intervention.